EXICURE, INC. Deferred Income Tax Liabilities, Net
EXICURE, INC. (XCUR) had Deferred Income Tax Liabilities, Net of $423.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:DeferredIncomeTaxLiabilitiesNet · last filed 2026-08-14
- 2026-06-30: Deferred Income Tax Liabilities, Net $423.00K.
- 2026-03-31: Deferred Income Tax Liabilities, Net $423.00K.
- 2025-12-31: Deferred Income Tax Liabilities, Net $423.00K.
- 2024-12-31: Deferred Income Tax Liabilities, Net $0.00.
| Period end | Deferred Income Tax Liabilities, Net |
|---|---|
| 2026-06-30 | $423.00K 10-Q · filed 2026-08-14 |
| 2026-03-31 | $423.00K 10-Q · filed 2026-05-29 |
| 2025-12-31 | $423.00K 10-Q · filed 2026-08-14 |
| 2024-12-31 | $0.00 10-K · filed 2026-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |